While the experimentation of the medical use of cannabis framed by the National Agency for Medicines began in France on March 31, 2021, DelleD, a French start-up committed to therapeutic cannabis for more than five years, created in 2014, develops cannabis-based drugs to support patients refractory to available therapies. Drugs that should enter the human testing phase by 2022.
DelleD’s health project, called LaFleur, involves the creation of a research laboratory and an industrial production site for cannabis-based health products. The idea is to combine agronomic research with medical development. Find out more about LaFleur: lafleur.bio